franckreporter/iStock via Getty Images
- IMV (IMV) +19% from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL.
- Nexalin Technology (NXL) +16%.
- AgileThought (AGIL) +10%.
- Reviva Pharmaceuticals Holdings (RVPH) +8% announces positive safety data from Drug-Drug Interaction Clinical Study of Brilaroxazine.
- AbCellera Biologics (ABCL) +8% stock rises on team up with AbbVie to discover antibody therapies.
- Top Ships (TOPS) +7%.
- TuSimple Holdings (TSP) +6%.